News

Media

Conferences

Publications

Clinical

Events

Resources

Medicare Part D and Oncology

February 27, 2017

By Lauren Santye, Assistant Editor

Video

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Recent Videos

Naloxone concept represented by wooden letter tiles.

Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication

Image credit: Gorodenkoff | stock.adobe.com

Pharmacist and Patient in Pharmacy | Image Credit: Gorodenkoff - stock.adobe.com

Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com

Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com

Image Credit: © Anastasiia - stock.adobe.com

Consent Preferences

Clinical Forums

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.